LiteHaus Translational 360 Engine::
Case study #1
Clinical due diligence (DD) for investment into a rare disease therapy: A pharma company was evaluating a small molecule therapy for potential investment. The therapy was in Phase III trials for a pediatric neurodegenerative rare disease and the company wanted to take expert opinion from a KOL as one data point in their technical DD.
The LiteHaus360 search engine jumped into action and in a matter of minutes, generated content documenting the latest scientific literature, disease pathology, clinical evidence, pharma company pipelines, available treatment alternatives as well as geolocation mapping of labs and sites involved in scientific and clinical research in the disease area.
LiteHaus identified several research clusters – for example, one at University of Pennsylvania, one at Universidad Autónoma de Madrid in Spain and one at Monash University in Australia.
Several KOLs were contacted and within a span of 12 hours, a Professor and Head of Regenerative Neuroscience and Development responded, and a call was scheduled in 48 hours, thereby completing a key aspect of scientific DD.
Case study #2
Clinical guidelines in precision medicine: LiteHaus was utilized to create insights on current best practices in the treatment of Gastrointestinal Cancers. The platform analyzed clinical data and created a decision tree to address questions such as -
#1. What are the 1st, 2nd and 3rd-line treatment options for patients with advanced hepatocellular cancer (HCC), Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) Performance Status PS 0-1?
#2. What are the alternatives for patients if Atezolizumab and Bevacizumab are contraindicated?
#3. When can doublet therapy with Gemcitabine and Capecitabine or monotherapy with Gemcitabine alone or Fluorouracil plus Folinic Acid alone can be offered?
#4. When should checkpoint inhibitors such as Nivolumab and Ipilimumab be used?
… and so on (representative data)
The analysis was used to identify potential treatment strategies for different patient populations based on distinct clinical parameters.